Discovery of 6-Deoxydapagliflozin as a Highly Potent Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Publisher： Bentham Science Publishers

E-ISSN： 1875-6638|10|3|304-317

ISSN： 1573-4064

Source： Medicinal Chemistry, Vol.10, Iss.3, 2014-05, pp. : 304-317

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for New Anti-Diabetic Agent

By  

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 4, 2010-03 ,pp. : 411-418

Bentham Science Publishers

Access to resources Recommend Favorite

Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

By Lamos Elizabeth M  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 6, 2013-06 ,pp. : 763-775

Informa Healthcare

Access to resources Recommend Favorite

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

By Lamos Elizabeth M   Younk Lisa M   Davis Stephen N  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 6, 2014-06 ,pp. : 875-882

Informa Healthcare

Access to resources Recommend Favorite

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

By Boyle Luke D   Wilding John PH  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 375-391

Informa Healthcare

Access to resources Recommend Favorite

Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

By Veltkamp Stephan A.  

Clinical Drug Investigation, Vol. 31, Iss. 12, 2011-12 ,pp. : 839-851

Adis International

Access to resources Recommend Favorite